FIELD: chemistry.
SUBSTANCE: oral pharmaceutical compositions containing rifamycin SV or a pharmaceutically acceptable salt thereof, characterized in that they are formulated at a higher concentration (approximately 600 mg/tablet) and so as to obtain a modified proximal intestinal profile of rifamycin SV or a pharmaceutically acceptable salt thereof, that is, in the small intestine (duodenum, jejunum, and ileum). In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment of a subject's small bowel bacterial overgrowth syndrome (SIBO) and/or irritable bowel syndrome (IBS), and/or in the treatment of cholera. In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment of a subject's hepatic encephalopathy, cirrhosis, pouchitis, and/or spontaneous bacterial peritonitis.
EFFECT: in one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment of a subject's non-alcoholic fatty liver disease, non-alcoholic fatty liver, or non-alcoholic steatohepatitis.
16 cl, 4 dwg, 14 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING INTESTINAL DISEASES | 2009 |
|
RU2519649C2 |
SOLID COMPOSITION FOR DELIVERY | 2018 |
|
RU2812928C2 |
METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | 2010 |
|
RU2582940C2 |
GASTRO-RESISTANT DOSAGE FORMS FOR ORAL ADMINISTRATION WITH CONTROLLED RELEASE | 2018 |
|
RU2812901C2 |
PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI | 2014 |
|
RU2671400C2 |
ANTIMETANOGENIC COMPOSITIONS AND USE THEREOF | 2015 |
|
RU2697851C2 |
KAPPA-OPIOID AGONISTS FOR TREATMENT OF DIARRHEA-PREVAILING IRRITABLE BOWEL SYNDROME AND ALTERNATE IRRITABLE BOWEL SYNDROME | 2008 |
|
RU2441655C2 |
APPLICATION OF METHYL NALTREXONE FOR TREATING IRRITABLE COLON SYNDROME | 2004 |
|
RU2373936C2 |
STABLE COMPOSITIONS OF DIGESTIVE ENZYMES | 2008 |
|
RU2445952C2 |
METHODS FOR TREATMENT OF DOOSE SYNDROME, USING FENFLURAMINE | 2018 |
|
RU2784524C2 |
Authors
Dates
2023-03-31—Published
2018-11-07—Filed